DALLAS--(BUSINESS WIRE)--Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, clinical-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the ...
DALLAS--(BUSINESS WIRE)--Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, clinical-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the ...
Overview The field of AAV-based gene therapy for lung diseases is evolving rapidly. Historically limited by biological barriers such as mucus and immune surveillance, lung-targeted gene delivery is ...
The Nature Index 2026 Research Leaders reveal the leading institutions and countries/territories in the natural sciences, health sciences, applied sciences and social sciences, according to their ...
Taysha to have an exclusive option on new payloads, constructs, and intellectual property arising from research conducted under the agreement Agreement leverages Taysha’s existing partnership with UT ...
Collaboration with Cleveland Clinic to support creation of novel next-generation mini-gene platform to pursue monogenic diseases not addressable by conventional AAV gene therapy technologies ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results